

Opioid Treatment Providers (OTP)

Policy ID:	HWC-PA-RP-020
Approved By:	Highmark Wholecare – Market Leadership
Provider Notice Date:	11/08/2024, 07/27/2026
Original Effective Date:	12/06/2024
Annual Approval Date:	12/2024, 10/01/2026
Last Revision Date:	10/2024, 06/2026
Products:	Pennsylvania Medicare
Application:	All participating hospitals and providers
Page Number(s):	1 of 3

Disclaimer

Highmark Wholecare medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

POLICY STATEMENT

This policy provides information regarding the coverage of, as determined by applicable federal and/or state legislation.

This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person's unique clinical circumstances warrant individual consideration, based upon review of applicable medical records.

The qualifications of the policy will meet the standards of the National Committee for Quality Assurance (NCQA) and the Pennsylvania Department of Health (DHS) and all applicable state and federal regulations.

DEFINITIONS

Highmark Wholecare – Managed care organization serving vulnerable populations that have complex needs and qualify for Medicaid. Highmark Wholecare members include individuals and families with low income, expecting mothers, children, and people with disabilities. Members pay nothing to very little for their health coverage. Highmark Wholecare currently services Pennsylvania Medicaid: PA HealthChoices.

Opioid Treatment Programs (OTP): as defined by CMS, healthcare entities that focus on providing medication-assisted treatment for people diagnosed with Opioid Use Disorder (OUD). OTPs must be certified by SAMHSA and accredited by an independent, SAMHSA-approved accrediting body.

OUD Treatment Services: items and services furnished by an OTP, as set forth in subparagraphs (A) through (F) of section 1861(jjj) (1) of the Social Security Act.

SAMHSA: Substance Abuse and Mental Health Services Administration

PROCEDURES

Prior Authorization may be required. Please validate codes on the Prior Authorization Lookup Tool

<https://providers.highmark.com/wholecare/provider-resources/prior-authorization-code-lookup>

As per CMS guidelines Highmark Wholecare shall allow reimbursement to Opioid Treatment Programs (“OTP”) for bundled payments of medically necessary Opioid Use Disorder (“OUD”) Treatment Services in an episode of care.

OTPs must meet the following requirements at the date of service to the member to bill for bundled payments of OUD Treatment Services:

- Be enrolled in the Medicare program.
- Have in effect a certification by the Substance Abuse and Mental Health Services Administration (SAMHSA) for the opioid treatment program.
- Be accredited by an accrediting body approved by the SAMHSA.

Claims for bundled payment of OUD Treatment services should include Place of Service Code 58 (Nonresidential Opioid Treatment Facility – a location that provides treatment for OUD on an ambulatory basis. Services include methadone and other forms of Medication Assistance Treatment (MAT).

As per CMS guidelines, payment for medications or services delivered, administered or dispensed to a member as part of the OTP bundled payment are considered to be a duplicative payment if delivery, administration or dispensing of the same medications or services were also separately paid by Gateway. Any duplicate payments will be recovered from the OTP.

Post-payment Audit Statement

The medical record must include documentation that reflects the medical necessity criteria and is subject to audit by Highmark Health Options at any time pursuant to the terms of your provider agreement.

Place of Service: Outpatient

CODING REQUIREMENTS

CPT code	Description
G1028	Take-home supply of nasal naloxone; 2-pack of 8 mg per 0.1 ml nasal spray (provision of the services by a Medicare-enrolled Opioid Treatment Program); list separately in addition to code for primary procedure
G2213	Initiation of medication for the treatment of opioid use disorder in the emergency department setting, including assessment, referral to ongoing care, and arranging access to supportive services (list separately in addition to code for primary procedure)

G2215	Take home supply of nasal naloxone; 2-pack of 4 mg per 0.1 ml nasal spray (provision of the services by a Medicare-enrolled Opioid Treatment Program); list separately in addition to code for primary procedure.
G2216	Take home supply of injectable naloxone (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure

Place of service Code

Description	
58	Nonresidential Opioid Treatment Facility

REIMBURSEMENT

Participating facilities will be reimbursed per their Highmark Wholecare contract.

Reference

CMS, *Medicare Program; CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations Final Rule; and Coding and Payment for Evaluation and Management, Observation and Provision of Self-Administered Esketamine Interim Final Rule*, <https://www.federalregister.gov/documents/2019/11/15/2019-24086/medicare-program-cy-2020-revisions-topayment-policies-under-the-physician-fee-schedule-and-other> (published 11/15/2019)

CMS, *Opioid Treatment Programs*, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/OpioidTreatment-Program/index> (last updated 11/26/2019)

SAMHSA, *Certification of Opioid Treatment Programs*, <https://www.samhsa.gov/medication-assistedtreatment/opioid-treatment-programs> (last updated 9/28/2015)